范围(计算机科学)
药物发现
变革型领导
生化工程
托换
机制(生物学)
蛋白质降解
计算生物学
风险分析(工程)
生物技术
生物
计算机科学
细胞生物学
业务
工程类
生物信息学
政治学
认识论
哲学
土木工程
程序设计语言
公共关系
作者
Scott J. Hughes,Andrea Testa,Nicola Thompson,Ian Churcher
标识
DOI:10.1016/j.drudis.2021.08.006
摘要
The transformational mechanism of action underpinning targeted protein degradation strategies, including proteolysis-targeting chimeras (PROTACs), gives potential for potent in vivo pharmacology and has allowed projects to move rapidly to the clinic. Despite this remarkable progress, there remain many opportunities to improve current, first-generation approaches even further. Our expanding knowledge will allow discovery of new degrading mechanisms with potential to address several limitations of current approaches, including improving scope and efficiency of degradation, improving drug-like properties of degraders, and reducing potential for the emergence of acquired resistance. Here, we discuss potential routes to realize these advances to expand TPD utility even further.
科研通智能强力驱动
Strongly Powered by AbleSci AI